Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells
- PMID: 16461842
- DOI: 10.1161/CIRCULATIONAHA.105.591743
Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells
Abstract
Background: Lipoproteins containing apolipoprotein (apo) CIII predict coronary heart disease and associate with components of the metabolic syndrome. ApoCIII inhibits lipoprotein catabolism in plasma. However, it is unknown whether apoCIII itself, or in association with VLDL, LDL, or HDL, directly affects atherogenic mechanisms in vascular cells. Thus, we investigated the direct effect of lipoproteins that do or do not have apoCIII, and apoCIII itself, on adhesion of THP-1 cells, a human monocytic cell line, to vascular endothelial cells (ECs).
Methods and results: VLDL CIII+ and LDL CIII+ (100 microg apoB/mL) from fasting plasma of 18 normolipidemic volunteers increased THP-1 cell adhesion to ECs under static conditions by 2.4+/-0.3-fold and 1.8+/-0.7-fold, respectively (P<0.01), whereas VLDL or LDL without apoCIII did not affect THP-1 cell adhesion. ApoCIII (100 microg/mL), but not apoCI, apoCII or apoE, also increased THP-1 cell adhesion by 2.1+/-0.6-fold. Studies with human peripheral blood monocytes yielded similar results. ApoCIII also had strong proadhesive effects under shear flow conditions. VLDL CIII+, LDL CIII+, or apoCIII itself activated PKCalpha and RhoA in THP-1 cells, which resulted in beta1-integrin activation and enhancement of THP-1 cell adhesion. Interestingly, HDL CIII+ did not affect THP-1 cell adhesion, whereas HDL without apoCIII decreased their adhesion.
Conclusions: ApoB lipoproteins that contain apoCIII increase THP-1 cell adhesion to ECs via PKCalpha and RhoA-mediated beta1-integrin activation. These results indicate that apoCIII not only modulates lipoprotein metabolism but also may directly contribute to the development of atherosclerosis.
Similar articles
-
Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease.Curr Opin Lipidol. 2014 Feb;25(1):35-9. doi: 10.1097/MOL.0000000000000040. Curr Opin Lipidol. 2014. PMID: 24345989 Review.
-
Apolipoprotein CIII links dyslipidemia with atherosclerosis.J Atheroscler Thromb. 2009 Mar;16(1):6-11. doi: 10.5551/jat.e607. Epub 2009 Mar 5. J Atheroscler Thromb. 2009. PMID: 19262004 Review.
-
Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation.Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):219-25. doi: 10.1161/01.ATV.0000249620.68705.0d. Epub 2006 Oct 12. Arterioscler Thromb Vasc Biol. 2007. PMID: 17038637
-
Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells.Circulation. 2006 Aug 15;114(7):681-7. doi: 10.1161/CIRCULATIONAHA.106.622514. Epub 2006 Aug 7. Circulation. 2006. PMID: 16894036
-
Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women.J Clin Endocrinol Metab. 2004 May;89(5):2207-13. doi: 10.1210/jc.2003-031564. J Clin Endocrinol Metab. 2004. PMID: 15126543 Clinical Trial.
Cited by
-
Role of APOC3 3238C/G, APOB 12669G/A and SCARB1 1050C/T polymorphisms, their expression in patients of HIV-associated lipodystrophy.Heliyon. 2024 May 1;10(9):e30519. doi: 10.1016/j.heliyon.2024.e30519. eCollection 2024 May 15. Heliyon. 2024. PMID: 38742060 Free PMC article.
-
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia.Curr Atheroscler Rep. 2023 Dec;25(12):1101-1111. doi: 10.1007/s11883-023-01179-y. Epub 2023 Dec 14. Curr Atheroscler Rep. 2023. PMID: 38095804 Review.
-
Apolipoproteins as potential communicators play an essential role in the pathogenesis and treatment of early atherosclerosis.Int J Biol Sci. 2023 Aug 21;19(14):4493-4510. doi: 10.7150/ijbs.86475. eCollection 2023. Int J Biol Sci. 2023. PMID: 37781031 Free PMC article. Review.
-
PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk.Int J Mol Sci. 2023 Jan 24;24(3):2319. doi: 10.3390/ijms24032319. Int J Mol Sci. 2023. PMID: 36768645 Free PMC article.
-
Association of triglyceride/high-density lipoprotein cholesterol ratio with subclinical inflammation and 10-year cardiovascular disease risk as determined by Framingham risk scores in Korean male smokers.Biomol Biomed. 2023 Jul 3;23(4):689-697. doi: 10.17305/bb.2022.8135. Biomol Biomed. 2023. PMID: 36724015 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous